By Heather Landi
Walgreens' healthcare ambitions continue to grow as the pharmacy retail giant expands its reach into clinical trials, leveraging its vast trove of patient data, its technology assets and its retail locations. Industry CRO veteran Ramita Tandon, who is leading the new business line, spoke with Fierce Healthcare to lay out Walgreens' clinical trials strategy.
read more
By Max Bayer
Discussions and dialogues addressing efforts to increase diversity in biotech permeated this year's BIO, with new data indicating slight gains across the industry. Yet toxic tropes persist both in and out of the conference, underscoring how much room for improvement remains.
read more
By Conor Hale
Johnson & Johnson Vision announced its Acuvue Oasys Max 1-Day lenses have received regulatory green lights in the U.S., Canada and Europe.
read more
By Paige Minemyer
A newly unsealed whistleblower suit claims that multiple CVS Health subsidiaries coordinated to prevent members from accessing generic drugs in a bid to boost the bottom line.
read more
By Zoey Becker
Kyowa Kirin Co., a Japanese specialty pharma company, is reportedly considering a $1 billion asset sale.
read more
By Nick Paul Taylor
Roche's long-running attempt to show its anti-amyloid-beta antibody works very early in the Alzheimer's disease pathway has ended in defeat. The AC Immune-discovered candidate failed to improve outcomes in cognitively unimpaired individuals at high imminent risk for developing Alzheimer's symptoms.
read more
By Conor Hale
Distributed globally by Ascensia Diabetes Care, the implantable blood sugar tracking system is designed to offer long-term wear while also requiring fewer calibrations with fingerstick glucose readings.
read more
By Zoey Becker
Makena has been on the market for over ten years through the FDA's accelerated approval program despite findings of its ineffectiveness. Unlike some companies that have pulled their marketed meds, Covis Pharma isn't letting this one go.
read more
By James Waldron
Interim phase 1 results have sustained Checkpoint Therapeutics’ hopes for a second indication for its lead anti-PD-L1 antibody.
read more
By Andrea Park
Aidoc is on quite the hot streak. Just about two months after racking up its ninth FDA clearance for an artificial intelligence-powered radiology tool, the Israeli startup has re-upped its annual tradition of raising tens of millions of dollars.
read more
By Fraiser Kansteiner
In fiscal year 2021, the FDA sent out 70% of follow-up letters to manufacturing facilities within 90 days of an inspection. Over that same stretch, the regulator completed 48% of regulatory actions for facilities in need of follow-up within six months of inspection closing, the agency said in a new report. Both represented declines from the prior year.
read more
By Gabrielle Masson
Promontory Therapeutics has ditched its old name in an effort to “delimit” itself and is now doing what many others can’t—expanding.
read more
By Anastassia Gliadkovskaya
The bank will partner with nonprofit community development financial institutions to expand community health and primary care centers.
read more
